GlassScriptPhysician profile
Leila Miller
NPI 1568746139
$2,695.01
in general payments reported to CMS, 2019-2025
26 companies · $610 in 2025
The $610 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.24 · 2022: $617 · 2023: $689 · 2024: $703 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $558.35 | 2022-2025 | Nucala |
| Lilly USA, LLC | $381.13 | 2022-2024 | Taltz, Olumiant, Zepbound |
| Genzyme Corporation | $226.81 | 2023-2025 | |
| Janssen Biotech, INC. | $224.15 | 2023-2025 | Tremfya |
| Optinose US, INC. | $197.19 | 2021-2024 | |
| Revance Therapeutics, INC. | $184.38 | 2024 | Daxxify |
| Merz North America, INC. | $134.83 | 2022 | |
| Grifols USA, LLC | $104.69 | 2023-2024 | Xembify |
| Abbvie INC. | $100.20 | 2021-2025 | |
| Incyte Corporation | $93.07 | 2023-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $76.87 | 2024-2025 | Dupixent, Libtayo |
| Acclarent, INC | $74.64 | 2022 | |
| Janssen Pharmaceuticals, INC | $49.62 | 2024-2025 | Tremfya |
| Leo Pharma INC. | $36.32 | 2022-2023 | Adbry |
| Novartis Pharmaceuticals Corporation | $35.32 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $34.73 | 2023 | Winlevi |
| Hologic Sales and Service, LLC | $33.19 | 2023 | Coolseal Generator |
| Astrazeneca Pharmaceuticals LP | $30.34 | 2025 | |
| Amgen INC. | $22.21 | 2024 | Otezla |
| Medtronic, INC. | $20.91 | 2025 | Propel |
| Merck Sharp & Dohme LLC | $19.36 | 2023 | |
| Ucb, INC. | $14.41 | 2025 | Bimzelx |
| Bolder Surgical, LLC | $13.44 | 2022 | |
| Endogastric Solutions, INC | $12.96 | 2022 | |
| Allergan, INC. | $12.32 | 2021 | |
| Organon LLC | $3.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leila Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.